{"id":"W3088510493","doi":"10.1016/j.annonc.2020.08.638","title":"524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Tolerability; Internal medicine; Neutropenia; Phases of clinical research; Pharmacokinetics; Pharmacology; Pharmacodynamics; Pembrolizumab; Oncology; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008551013,0.0009537502,0.001390947,0.0001843082,0.0003165739,0.0006547487,0.0003585467,0.0005996707,0.00386841],"category_scores_gemma":[0.0008201791,0.0002877706,0.0008761135,0.0002241191,0.0004243438,0.0003487424,0.0002061691,0.002026148,0.001001227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005583546,"about_ca_system_score_gemma":0.0006505235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001584244,"about_ca_topic_score_gemma":0.003065021,"domain_scores_codex":[0.9997011,0.0001338903,0.00001389175,0.00004375733,0.00002782229,0.00007958856],"domain_scores_gemma":[0.9995914,0.0001324263,0.00003589093,0.00003407314,0.0000378146,0.000168414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3941499,0.05623782,0.02451321,0.0008145052,0.001706862,0.0009197131,0.0004591333,0.005933334,0.2632995,0.0004589676,0.01118927,0.2403177],"study_design_scores_gemma":[0.2256587,0.6167495,0.08279195,0.00005403844,0.001837808,0.001206955,0.0001477296,0.003046131,0.04710296,0.00044873,0.02087174,0.0000837827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880762,0.001742199,0.0009565183,0.000849471,0.0001563142,0.001095273,0.002138467,0.00008226087,0.00490322],"genre_scores_gemma":[0.9835386,0.001219644,0.002104874,0.001080061,0.0001621463,0.0009508086,0.006203827,0.00004967532,0.004690394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00386841,"threshold_uncertainty_score":0.01294106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08599711741859951,"score_gpt":0.4161967174254941,"score_spread":0.3301996000068946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}